LAPTM4B gene polymorphism and endometrial carcinoma risk and prognosis

References

• Amant F, Moerman P, Neven P, et al. (2005). Endometrial cancer. Lancet 366:491–505
   PubMed Web of Science ®Google Scholar
• Cheng XJ, Xu W, Zhang QY, Zhou RL. (2008). Relationship between LAPTM4B gene polymorphism and susceptibility of colorectal and esophageal cancers. Ann Oncol 19:527–32
   Google Scholar
• Deng LJ, Zhang QY, Liu B, Zhou RL. (2005). Relationship between LAPTM4B gene polymorphism and susceptibility of lung cancer. Beijing Da Xue Xue Bao 37:302–5
   Google Scholar
• Diaz-Padilla I, Amir E, Marsh S, et al. (2012). Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review. Gynecol Oncol 124:354–65
   Google Scholar
• Fan M, Liu Y, Zhou R, Zhang Q. (2012). Association of LAPTM4B gene polymorphism with breast cancer susceptibility. Cancer Epidemiol 36:364–8
   Google Scholar
• Gehrig PA, Bae-Jump VL. (2010). Promising novel therapies for the treatment of endometrial cancer. Gynecol Oncol 116:187–94
   PubMed Web of Science ®Google Scholar
• Hospital Authority. Hong Kong cancer registry web site. Available from: http://www3.ha.org.hk/cancereg/stat.asp [last accessed Sep 2008]
   Google Scholar
• Karageorgi S, Prescott J, Wong JY, et al. (2011). GSTM1 and GSTT1 copy number variation in population-based studies of endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 20:1447–52
   PubMed Web of Science ®Google Scholar
• Kasper G, Vogel A, Klaman I, et al. (2005). The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett 224:93–103
   Google Scholar
• Knappskog S, Trovik J, Marcickiewicz J, et al. (2012). SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. Eur J Cancer 48:1988–96
   PubMed Web of Science ®Google Scholar
• Konopka B, Janiec-Jankowska A, Kwiatkowska E, et al. (2011). PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors. Hum Pathol 42:1710–19
   PubMed Web of Science ®Google Scholar
• Li L, Wei XH, Pan YP, et al. (2010a). LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 29:5785–95
   PubMed Web of Science ®Google Scholar
• Li Y, Iglehart JD, Richardson AL, Wang ZC. (2012). The amplified cancer gene LAPTM4B promotes tumor growth and tolerance to stress through the induction of autophagy. Autophagy 8:273–4
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Q, Tian R, et al. (2011). Lysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cells. Cancer Res 71:7481–9
   Google Scholar
• Li Y, Zou L, Li Q, et al. (2010b). Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 16:214–18
   PubMed Web of Science ®Google Scholar
• Liu J, Zhou R, Zhang N, et al. (2000). Biological function of a novel gene overexpressed in human hepatocellular carcinoma. Chin Med J (Engl) 113:881–5
   Google Scholar
• Liu X, Xiong F, Wei X, et al. (2009). LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer Sci 100:2335–40
   Google Scholar
• Liu X, Zhou R, Zhang Q, et al. (2003). [Identification and characterization of LAPTM4B encoded by a human hepatocellular carcinoma-associated novel gene]. Beijing Da Xue Xue Bao 35:340–7
   Google Scholar
• Liu Y, Zhang QY, Qian N, Zhou RL. (2007). Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer. Ann Oncol 18:311–16
   Google Scholar
• Meng F, Luo C, Hu Y, et al. (2010a). Overexpression of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study. Int J Gynecol Pathol 29:587–93
   Google Scholar
• Meng F, Song H, Luo C, et al. (2011). Correlation of LAPTM4B polymorphisms with cervical carcinoma. Cancer 117:2652–8
   PubMed Web of Science ®Google Scholar
• Meng FL, Yin MZ, Song HT, et al. (2010b). LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. Int J Gynecol Cancer 20:745–50
   Google Scholar
• Shao GZ, Zhou RL, Zhang QY, et al. (2003). Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 22:5060–9
   Google Scholar
• Sherman ME. (2000). Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 13:295–308
   PubMed Web of Science ®Google Scholar
• Shiozawa T, Konishi I. (2006). Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment. Int J Clin Oncol 11:13–21
   PubMedGoogle Scholar
• Stern C. (1943). The Hardy-Weinberg law. Science 97:137–8
   PubMedGoogle Scholar
• Wang S, Zhang QY, Zhou RL. (2012). Relationship between LAPTM4B gene polymorphism and susceptibility of primary liver cancer. Ann Oncol 23:1864–9
   Google Scholar
• Yang H, Xiong F, Wei X, et al. (2010). Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer Lett 294:236–44
   Google Scholar
• Yang H, Xiong FX, Lin M, et al. (2009). LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 136:275–81
   Google Scholar
• Yang H, Zhai G, Ji X, et al. (2012). LAPTM4B allele *2 is a marker of poor prognosis following hepatic tumor resection for hepatocellular carcinoma. PLoS One 7:e34984
   Google Scholar
• Yin M, Li C, Li X, et al. (2011a). Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer. J Surg Oncol 104:29–36
   Google Scholar
• Yin M, Xu Y, Lou G, et al. (2011b). LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. Int J Cancer 129:629–35
   Google Scholar
• Zhai G, Yan K, Ji X, et al. (2012a). LAPTM4B allele *2 is a marker of poor prognosis for gallbladder carcinoma. PLoS One 7:e45290
   Google Scholar
• Zhai G, Yang H, Ji X, et al. (2012b). Correlation of LAPTM4B polymorphisms with hepatocellular carcinoma in Chinese patients. Med Oncol 29:2744–9
   Google Scholar
• Zhou L, He XD, Cui QC, et al. (2008). Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett 264:209–17
   Google Scholar
• Zhou L, He XD, Yu JC, et al. (2010). Overexpression of LAPTM4B promotes growth of gallbladder carcinoma cells in vitro. Am J Surg 199:515–21
   Google Scholar